Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Respiratory Biologics Market Expansion From $8.61 Billion In 2026 To $15.66 Billion In 2030
The respiratory biologics market has experienced rapid expansion in recent years. With a compound annual growth rate (CAGR) of 16.3%, its size is projected to increase from $7.41 billion in 2025 to $8.61 billion in 2026. This historic growth has been driven by the constraints associated with conventional inhalers, an uptick in severe asthma occurrences, approvals for biologic therapies, advancements in immunology research, and the proliferation of specialty clinics.
The respiratory biologics market is projected to experience significant expansion over the coming years, with an anticipated valuation of $15.66 billion by 2030, reflecting a compound annual growth rate (CAGR) of 16.1%. This upward trajectory in the forecast period is driven by factors such as the advancement of precision respiratory medicine, a broadening pipeline of biologic therapies, increased healthcare expenditures, enhanced reimbursement frameworks, and the demand to address unmet clinical needs in severe respiratory conditions. Key developments shaping this period include a growing preference for targeted biologic treatments, an expanded focus on managing severe asthma, the rising prominence of biomarker-driven patient selection strategies, a greater reliance on injectable respiratory medications, and a notable shift toward the utilization of long-acting biologic agents.
Download A Free Sample Report For Comprehensive Market Insights:
#Respiratory Biologics Market Growth Factors: Which Forces Are Supporting Market Expansion?
The expected increase in air pollution will drive expansion in the respiratory biologics market moving forward. Air pollution is defined as the presence of dangerous substances like gases, particulate matter, and biological molecules within Earth’s atmosphere, which can adversely affect human health and the environment. This phenomenon is worsening due to expanding industrialization and urbanization, which result in greater emissions of pollutants from factories, automobiles, and construction sites. Respiratory biologics address the health impacts of air pollution by delivering focused treatments that decrease inflammation and enhance lung function in people exposed to airborne contaminants. For example, in January 2025, the Environmental Protection Agency, a U.S. government organization, reported that the United States emitted over 66 million tons of pollutants into the atmosphere during 2023. Consequently, the growing level of air pollution is fueling the advancement of the respiratory biologics market.
Respiratory Biologics Market Segment Analysis And Revenue Opportunities
The respiratory biologics market covered in this report is segmented –
1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome
2) By Route Of Administration: Intravenous, Subcutaneous
3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies
Subsegments:
1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma
2) By Chronic Rhinosinasitis: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps
3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES
Respiratory Biologics Market Industry Trends: What Changes Are Reshaping Demand?
Key players in the respiratory biologics market are concentrating on the creation of advanced biologic treatments, including targeted immune therapies designed for chronic respiratory conditions, with the goal of delivering precise interventions that curb inflammation and enhance respiratory performance. These targeted immune therapies for chronic lung diseases work by regulating the immune system to alleviate swelling and ease breathing difficulties in persistent pulmonary disorders. As an example, in September 2024, Sanofi S.A., a pharmaceutical firm headquartered in France, disclosed that the U.S. Food and Drug Administration (FDA) had granted approval for Dupixent (dupilumab) as an additional maintenance therapy for adults suffering from inadequately managed chronic obstructive pulmonary disease (COPD) who exhibit an eosinophilic phenotype. This authorization represented a major breakthrough, as Dupixent was the first biologic medication cleared in the United States for addressing this particular subset of COPD patients.
Respiratory Biologics Market Leading Players Shaping Industry Direction
Major companies operating in the respiratory biologics market are Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Amgen Inc., Swedish Orphan Biovitrum AB, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Glenmark Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.
Access The Complete Respiratory Biologics Market Report:
Respiratory Biologics Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the respiratory biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model